Status:
UNKNOWN
Donepezil Double Blind Trial for ECT Memory Disfunction
Lead Sponsor:
BeerYaakov Mental Health Center
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT. Patients will be randomized to receive either donezepil or plasebo, in order to...
Eligibility Criteria
Inclusion
- Schizophrenia, Schizoaffective disorder, schizophreniform disorder patients who meet criteria for diagnoses by DSM-IV criteria and evaluated by the Structured Clinical Interview for DSM-IV (SCID)
Exclusion
- History of serious neurological disorders including neurodegenerative deseases, mental retardation, substance and/or alcohol dependence.
- Pregnant women
- Patients who recieved ECT within 6 month
- Patients whith contraindication to Donepezil treatment.
- Patients with Lithium treatment
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00465283
Start Date
May 1 2007
End Date
January 1 2010
Last Update
January 27 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beer Yaakov MHC
Beer Yaacov, Israel, 70350